Rosiglitazone initiation is contraindicated in patients with which condition?

Rosiglitazone initiation is contraindicated in patients with which condition?

• A. NYHA class III/IV heart failure due to fluid retention
• B. Stable angina
• C. NYHA class II heart failure
• D. Chronic kidney disease stage 3

Answer: (A)

Rosiglitazone is a thiazolidinedione that can cause fluid retention by promoting renal sodium reabsorption and expanding plasma volume. Starting it in patients with advanced heart failure (NYHA class III/IV) is contraindicated because these patients are particularly prone to edema and worsening heart failure, and TZD-induced fluid retention can trigger decompensation requiring hospitalization. In contrast, less severe heart failure (class II) or other conditions like stable angina or stage 3 chronic kidney disease do not carry the same absolute contraindication, though edema and heart‑failure risk still require caution and monitoring.

Rosiglitazone is a thiazolidinedione that can cause fluid retention by promoting renal sodium reabsorption and expanding plasma volume. Starting it in patients with advanced heart failure (NYHA class III/IV) is contraindicated because these patients are particularly prone to edema and worsening heart failure, and TZD-induced fluid retention can trigger decompensation requiring hospitalization. In contrast, less severe heart failure (class II) or other conditions like stable angina or stage 3 chronic kidney disease do not carry the same absolute contraindication, though edema and heart‑failure risk still require caution and monitoring.